| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | ||
| 3 | Generic | retifanlimab | |
| 4 | Indication | anal cancer; endometrial cancer, Merkel cell, NSCLC | |
| 5 | MOA | PD-1 mab | |
| 6 | Economics | MGNX | |
| 7 | Clinical Trials | ||
| 8 | Phase II "POD1UM-101" endometrial | ||
| 9 | |||
| 10 | Phase II "POD1UM-204" endometrial | ||
| 11 | |||
| 12 | Phase II "POD1UM-201" Merkel cell | ||
| 13 | |||
| 14 | Phase III "POD1UM-304" NSCLC | ||
| 15 | |||
| 16 | Phase III "POD1UM-303" SCAC |